TY - JOUR
T1 - From mice to men and back
T2 - An assessment of preclinical model systems for the study of lung cancers
AU - Gazdar, Adi F.
AU - Hirsch, Fred R.
AU - Minna, John D.
N1 - Funding Information:
Disclosure: This article was supported by National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant P50CA70907. The authors declare no other conflict of interest.
Publisher Copyright:
© 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc.
PY - 2016/3/23
Y1 - 2016/3/23
N2 - Introduction: Studies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses. Methods: We searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles. Results: Multiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models. Conclusions: A large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.
AB - Introduction: Studies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses. Methods: We searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles. Results: Multiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models. Conclusions: A large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.
KW - Cell Lines
KW - Cell lines
KW - Genetically Engineered Mouse Models
KW - Lung Cancer
KW - Neuroendocrine Carcinomas
KW - Non-Small Cell Lung Cancer
KW - Patient-Derived Xenografts
KW - Preclinical Models
KW - Small Cell Lung Cancer
UR - http://www.scopus.com/inward/record.url?scp=84962522570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962522570&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2015.10.009
DO - 10.1016/j.jtho.2015.10.009
M3 - Review article
C2 - 26723239
AN - SCOPUS:84962522570
SN - 1556-0864
VL - 11
SP - 287
EP - 299
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 3
ER -